No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

byTeddy Guo

December 21, 2021

in StudyGraphics

Reading Time: 1 min read

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

RelatedReports

StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified

AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025

Nivolumab may be effective in platinum-resistant ovarian cancer

Nedaplatin-based concurrent chemoradiotherapy is noninferior to cisplatin-based therapy in patients with locoregional nasopharyngeal carcinoma

Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

Quantitative flow ratio-guided coronary intervention reduces the rate of major cardiac events compared to visual angiography

Many new pediatric asthma cases attributable to obesity

Once-a-week cagrilintide is effective for weight management in overweight and obese patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports